CANGRELOR

CANGRELOR Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  Anti-platelet agent.

• Verwenden

  Cangrelor is a P2Y12 inhibitor used as an antiplatelet drug for intravenous application.

• Definition

  ChEBI: A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.

• Clinical Use

  Direct P2Y12 platelet receptor antagonist:
  
  Antiplatelet for patients undergoing a PCI

• Stoffwechsel

  Cangrelor is deactivated rapidly in the plasma by dephosphorylation to form its main metabolite, a nucleoside. Following a 2 micrograms/kg/min infusion of [3 H] cangrelor, 58% was found in urine and the remaining 35% was found in faeces, presumably following biliary excretion.

CANGRELOR Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(89)Suppliers

163706-06-7, CANGRELOR Verwandte Suche: